10 completed, 4 recruiting, 2 active not recruiting, 1 enrolling by invitation. 19 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 10, Recruiting 4, Active not recruiting 2, Enrolling by invitation 1, Not yet recruiting 1, Unknown 1 |
| Phase 1 | 4 | Active not recruiting 2, Completed 2 |
Follow Healthy Volunteer: new trials by email Literature Review of Healthy Volunteer trials Research Report on Healthy Volunteer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Meal Macronutrients on Postprandial Lipids High carb then high fat breakfast, High fat then high carb breakfast - Nephrotic Syndrome, Lipodystrophy | Phase 2 | Not yet recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 100 | 2026-11-01 | 2026-10-27 |
| Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study Dolutegravir (DTG) AND Tenofovir alafenamide (TAF), Tenofovir Disoproxil Fumarate, Dolutegravir - Healthy Volunteer, Weight Gain | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 120 | 2026-09-24 | 2026-09-29 |
| Novel Biomarkers of Non-IgE Immediate Hypersensitivity Drug Reactions Vancomycin (IV) - Healthy Volunteer, Hypersensitivity Reactions | Phase 1 / Phase 2 | Active not recruiting | Johns Hopkins University | 25 | 2026-05-21 | 2026-10-27 |
| Ultralow Dose PET Imaging of 18F-flurpiridaz 18F-flurpiridaz - Healthy Volunteer, Coronary Arterial Disease | Phase 2 | Enrolling by invitation | Akiva Mintz | 200 | 2025-12-16 | 2026-04-13 |
| Ultralow Dose PET Imaging for 18F-NaF Uptake 18F-NaF - Healthy Volunteer, Bone Alteration | Phase 2 | Recruiting | Akiva Mintz | 200 | 2025-09-01 | 2025-12-16 |
| Ultralow Dose PET Imaging for PSMA Expression Piflufolastat F18 - Healthy Volunteer, Prostate CA | Phase 2 | Recruiting | Akiva Mintz | 200 | 2025-05-12 | 2025-06-04 |
| Ultralow Dose PET Imaging of 18F-FDG Uptake 18F-FDG - Healthy Volunteer, Cancer | Phase 2 | Recruiting | Akiva Mintz | 200 | 2025-05-12 | 2025-06-04 |
| Defining a PK and PD Model for Peripheral Analgesia After IV Oxytocin Oxytocin - Acute Pain, Chronic Pain | Phase 2 | Completed | Wake Forest University Health Sciences | 25 | 2023-08-17 | 2025-10-28 |
| A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05 Low Dose TP-05, High Dose TP-05, Placebo Comparator - Healthy Volunteer | Phase 2 | Completed | Tarsus Pharmaceuticals, Inc. | 30 | 2022-12-12 | 2024-09-19 |
| Evaluation of the Immunogenicity and Safety BBIBP-CorV Vaccine for COVID-19 in Adults in Guinea BBIBP-CorV - COVID-19, Vaccine Adverse Reaction | Phase 2 | Unknown | ANRS, Emerging Infectious Diseases | 200 | 2022-04-25 | 2024-03-27 |
| Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers Tradipitant, Placebo - Healthy Volunteer | Phase 1 / Phase 2 | Completed | Vanda Pharmaceuticals | 27 | 2021-02-01 | 2024-04-16 |
| Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine Flucelvax, Fluvirin, Fluzone High Dose - Healthy Volunteer | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 98 | 2019-10-02 | 2024-01-02 |
| Safety, Pharmacokinetic, and Pharmacodynamic Study of TS-142 in Healthy Subjects Step 1: TS-142, Step 2: TS-142, Step 2: Placebo - Healthy Volunteer | Phase 2 | Completed | Taisho Pharmaceutical Co., Ltd. | 23 | 2019-09-17 | 2025-02-28 |
| Study to Compare Active Tymbion Iontophoresis to Sham Tymbion Iontophoresis for Anesthesia of the Tympanic Membrane Tymbion Lidocaine/epinephrine solution, Device: Iontophoresis System (IPS) with Drug: Tymbion lidocaine/epinephrine solution - Healthy Volunteer | Phase 2 | Completed | Tusker Medical | 40 | 2017-04-27 | 2020-01-18 |
| Evaluation of D3 Receptor Occupancy Using FLUORTRIOPRIDE ([18F]FTP) PET/CT [18F]FTP PET/CT - D3 Dopamine Receptor, Cocaine-dependent | Phase 1 / Phase 2 | Active not recruiting | University of Pennsylvania | 30 | 2016-06-01 | 2026-08-10 |
| A Study of MHAA4549A in Healthy Volunteers in an Influenza Challenge Model MHAA549A, Placebo, oseltamivir [Tamiflu] - Healthy Volunteer | Phase 2 | Completed | Genentech, Inc. | 101 | 2013-11-25 | 2017-03-09 |
| Effects of Interrupting Sedentary Behavior on Metabolic and Cognitive Outcomes in Children Walking on a Treadmill, Sedendary Activities Only - Healthy Volunteer | Phase 1 / Phase 2 | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 89 | 2013-06-26 | 2018-01-31 |
| Multiple Dose Pharmacokinetics of LCZ696 and Its Metabolites in Subjects With Severe Renal Impairment vs. Matched Healthy Subjects With Normal Renal Function LCZ696A - Pharmacokinetics, Renal Impaired | Phase 2 | Completed | Novartis Pharmaceuticals | 12 | 2009-03-01 | 2015-09-29 |
| Acamprosate to Reduce Symptoms of Alcohol Withdrawal NMR-spectroscopy, Oral acamprosate - Alcohol-Related Disorders, Alcohol Dependence | Phase 2 | Completed | National Institutes of Health Clinical Center (CC) | 56 | 2005-03-01 | 2012-01-12 |
COVID-19 (2) · Acute Pain (1) · Alcohol-Related Disorders (1) · Alcoholism (1) · Arthritis (1) · Chronic Pain (1) · Diabetes Mellitus (1) · Hypersensitivity (1) · Insulin Resistance (1) · Lipodystrophy (1) · Lyme Disease (1) · Metabolic Syndrome (1) · Motor Activity (1) · Myocardial Infarction (1) · Myocardial Ischemia (1)
Pathological Conditions, Signs and Symptoms (4) · Infections (3) · Signs and Symptoms (3) · Body Weight (2) · Coronaviridae Infections (2) · Coronavirus Infections (2) · Glucose Metabolism Disorders (2) · Hyperinsulinism (2) · Lung Diseases (2) · Male Urogenital Diseases (2) · Metabolic Diseases (2) · Nidovirales Infections (2) · Nutritional and Metabolic Diseases (2) · Pneumonia (2) · Pneumonia, Viral (2)
Magnetic Resonance Spectroscopy (5) · Blood Specimen Collection (4) · 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid (1) · Acamprosate (1) · BIBP COVID-19 vaccine (1) · Epinephrine (1) · Fluorodeoxyglucose F18 (1) · Fluzone High-Dose (1) · Influenza Vaccines (1) · Lidocaine (1) · Myo-Inositol-1-Phosphate Synthase (1) · Oseltamivir (1) · Oxytocin (1) · Tenofovir (1) · Vancomycin (1)
Akiva Mintz (4) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · ANRS, Emerging Infectious Diseases (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Genentech, Inc. (1) · Johns Hopkins University (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · National Institutes of Health Clinical Center (CC) (1) · Novartis Pharmaceuticals (1) · Taisho Pharmaceutical Co., Ltd. (1) · Tarsus Pharmaceuticals, Inc. (1) · Tusker Medical (1) · University of Pennsylvania (1) · Vanda Pharmaceuticals (1) · Wake Forest University Health Sciences (1)
United States (15) · Germany (1) · Guinea (1) · Japan (1) · Russia (1) · Serbia (1) · United Kingdom (1)
Abdoul Habib Beavogui (1) · Brian P Epling, M.D. (1) · Jack A Yanovski, M.D. (1) · Jacob Dubroff, MD PhD (1) · James C Eisenach, MD (1) · Kavita Dhamdhere, MD, PhD (1) · Linden Hu, MD (1) · Melanie Dispenza, MD, PhD (1) · Odile Launay (1) · Rachel D Sparks, M.D. (1) · Rebecca J Brown, M.D. (1)
PMID 20921123, PMID 26312582, PMID 28639229, PMID 28807912, PMID 29960116, PMID 30280905, PMID 35644931, PMID 36599369, PMID 37563858
P01NS119159 (1), R21AI182531 (1)